The Vision Research Foundation (VRF) has been recognized as a patentee for developing a novel method to quantitate the Human Cytomegalovirus (HCMV) in clinical specimens. Spearheaded by Dr. HN Madhavan, President, VRF, microbiology scientists have developed the Multiple Polymerase Chain Reaction for rapid detection and specific identification of the HCMV which is found in immuno-compromising diseases.
HCMV is an important cause of morbidity and occasional mortality in immunocompromised patients such as transplant recipients, neonates with congenital HCMV disease and patients infected with the Human Immunodeficiency Virus (HIV).
Quantitation of HCMV plays an important role in identifying patients at high risk for developing diseases and also for assessing the response to antiviral treatment.
While there are several quantitative competitive methods available for quantitation by PCR, to accurately determine the systemic and site-specific HCMV load, these are technically difficult to carry out, on a routine basis, in clinical laboratories, time consuming and require a good amount of expertise. In contrast, the novel semi-quantitative method, developed by microbiology scientists at VRF, is a cost-effective method that allows the rational use of preemptive therapy for patients at high risk of developing symptomatic disease. This method is also applicable, more easily, to laboratories in which PCR is regularly carried out.